

AMENDMENTS

IN THE CLAIMS:

Please cancel claims 2-11 and 15-19.

Please add new claims 20-26 as follows:

Sub E1
D1

20. A fusion protein comprising (i) an antigenic protein derived from Mycoplasma gallisepticum causing an antibody-antigen reaction with Mycoplasma gallisepticum immune serum or Mycoplasma gallisepticum infected serum and (ii) a signal polypeptide of Herpesvirus outer membrane protein, said signal polypeptide being ligated with said antigenic protein derived from Mycoplasma gallisepticum at the N terminus thereof.

21. A fusion protein according to claim 20, wherein a sequence of said antigenic protein is amino acids 64-456 of SEQ ID NO:2 or amino acids 693-1086 of SEQ ID NO:4.

22. A fusion protein according to claim 20, wherein said signal polypeptide is derived from a herpes virus showing infection to fowl.

Sub E2

23. A fusion protein according to claim 22, wherein said signal polypeptide is derived from a Marek's disease virus.

24. A fusion protein according to claim 23, wherein said signal polypeptide is gB protein derived from a Marek's disease virus.

Sub E3

25. A recombinant Avipox virus in which a DNA coding for the fusion protein according to claim 20 has been inserted.

26. A recombinant live vaccine for anti-fowl Mycoplasma gallisepticum infection comprising as an effective ingredient a recombinant Avipox virus in which a DNA coding for the

fusion protein according to claim 20 has been inserted, wherein the fusion protein is capable, upon administration into a host cell, of immunizing that cell against subsequent infection with Mycoplasma gallisepticum.
